Senior Consultant on Medical Oncology, Portuguese Institute of Oncology, Lisbon (IPOLFG,EPE)
Coordinator of the Breast/Ovarian Risk evaluation Clinic (IPOLFG,EPE).
Coordinator of the Hereditary Breast/Ovarian Group at the Molecular Unit (IPOLFG,EPE).
Invited Assistant on Medical Oncology, Nova Medical School of Lisbon

Master in Science (Bioethics), KU Leuven, Belgium.

Member, Executive (since 2011) and Plenary  (2007) Committee, National Commission for Clinical research (CEIC). 
Invited member,  Local Ethics Committee, IPOLFG, EPE (2008). 

Selected Papers
Human Natural Killer Cell Development in a Xenogeneic  Culture System. Barão, I., Vaz, F  et al.Br J of Haematol, 2002, 118(3): 885.
Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. Machado, PM.,  Brandão,RD.,   Cavaco,B.,  Eugenio, J., Bento,S., Nave,M.,  Fernandes,A  and  Vaz, F. J Clin Oncol 2007:2027.
Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. F Vaz et al. J Histochem Cytochem. 2007; 55(11):1105.
10- Report from Subgroup Education, Training, Infrastructure and Patient Involvement under OECD GSF Working Group to facilitate International Cooperation in Non-Commercial Clinical Trials. Melin O, Aotani E, Anderiesz C, Bertoye P-H, Cazap E, Chan A, Ghersi D, Gouya G, Isaac M, Kvalheim G, Makanga M, Nam B-H, Ren J, Siegfried N, Steinhausen K, Stuart G C E, Vallikad E, Vaz F, Vella S, Wolzt M, Trimble E L. Trials. Jpn J Pharmacol Ther vol. 40 Suppl 2012.
13- Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Cuzick J et al,  on behalf of the IBIS-II investigators. Lancet, 2014 (383):1041–1048.DOI: http://dx.doi.org/10.1016/S0140-6736(13)62292-8. A minha colaboração neste artigo e no ensaio está expressa no apêndice do mesmo. 
14- Men seeking counseling in a Breast Cancer Risk Evaluation Clinic. A C Freitas,  Ana Opinião,Sofia Fragoso, Hugo Nunes, Madalena Santos, Ana Clara,Sandra Bento, Ana Luis, Jorge Silva, Cecília Moura, Bruno Filipe, Patrícia Machado, Sidónia Santos,Saudade André, Paula Rodrigues, Joana Parreira, and Fátima Vaz.   Ecancermedicalscience. 2018; 12: 804.